{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:18:19Z","timestamp":1790936299527,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":77,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatrics International"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objective<\/jats:title>\n                    <jats:p>Intravitreal injection of anti\u2010vascular endothelial growth factor (VEGF) antibodies is widely used to treat retinopathy of prematurity (ROP), yet, its systemic effects remain unclear. In adults, intravitreal anti\u2010VEGF therapy has been associated with proteinuria and acute kidney injury. This study aimed to evaluate the renal effects of anti\u2010VEGF antibody (Ranibizumab) by longitudinally measuring urinary biomarkers and serum VEGF levels in preterm infants with ROP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Preterm infants were categorized into two groups based on ROP treatment status: those receiving intravitreal ranibizumab (IVR) (treated group) and age\u2010matched controls without treatment (nontreated group). Urinary biomarkers, including angiotensinogen, liver\u2010type fatty acid\u2010binding protein (L\u2010FABP), albumin, and podocalyxin, were assessed at three time points: before treatment, and at one and 2 months post\u2010IVR. Serum VEGF levels were measured 1 month post\u2010IVR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 30 infants in the treated group and 12 in the nontreated group. The mean gestational age and birth weight were 24.9\u2009weeks and 664\u2009g in the treated group, and 26.8\u2009weeks and 845.6\u2009g in the nontreated group. The mean postnatal age at treatment was 68.8\u2009days, with a postmenstrual age of 34.8\u2009weeks. No significant differences were observed in urinary biomarker levels between the groups at one and 2 months posttreatment. Serum VEGF levels were higher in the treated group than in the nontreated group after IVR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IVR treatment did not show the sustained renal injury or suppress serum VEGF levels in preterm infants with ROP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ped.70366","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:55:13Z","timestamp":1773906913000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Urinary biomarkers and serum\n                    <scp>VEGF<\/scp>\n                    in preterm infants with retinopathy of prematurity treated with ranibizumab"],"prefix":"10.1111","volume":"68","author":[{"given":"Mitsuhide","family":"Nagaoka","sequence":"first","affiliation":[{"name":"Division of Neonatology, Maternal and Perinatal Center Toyama University Hospital  Toyama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9937-1703","authenticated-orcid":false,"given":"Taketoshi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Maternal and Perinatal Center Toyama University Hospital  Toyama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Niimi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Fukuoka University Hospital  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akane","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Hiroshima Citizens Hospital  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiko","family":"Maeno","sequence":"additional","affiliation":[{"name":"Department of Neonatology Hiroshima Prefectural Hospital  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Miyazono","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Tsukuba University Hospital  Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Inomata","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Maternal and Perinatal Center Toyama University Hospital  Toyama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukako","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Maternal and Perinatal Center Toyama University Hospital  Toyama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0418-9985","authenticated-orcid":false,"given":"Kentaro","family":"Tamura","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Maternal and Perinatal Center Toyama University Hospital  Toyama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Public Health, Faculty of Medicine University of Toyama  Toyama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.21037\/tp.2019.07.10","article-title":"The clinical management and outcomes of extremely preterm infants in Japan: past, present, and future","volume":"8","author":"Isayama T","year":"2019","journal-title":"Transl Pediatr"},{"key":"e_1_2_13_3_1","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.18240\/ijo.2021.08.17","article-title":"Survey of current retinopathy of prematurity practices in China","volume":"14","author":"le TP","year":"2021","journal-title":"Int J Ophthalmol"},{"key":"e_1_2_13_4_1","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.ophtha.2022.06.008","article-title":"Retinopathy of prematurity treatment trends from 2003 to 2020 in the United States","volume":"129","author":"Khan SI","year":"2022","journal-title":"Ophthalmology"},{"key":"e_1_2_13_5_1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.oret.2023.12.002","article-title":"Treated cases of retinopathy of prematurity in Germany: 10\u2010year data from the retina.Net retinopathy of prematurity registry","volume":"8","author":"Pfeil JM","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"e_1_2_13_6_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.101018","article-title":"Assessment and management of retinopathy of prematurity in the era of anti\u2010vascular endothelial growth factor (VEGF)","volume":"88","author":"Tsai AS","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"e_1_2_13_7_1","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF\u20101 in infants with retinopathy of prematurity","volume":"56","author":"Kong L","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_13_8_1","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1167\/iovs.15-18528","article-title":"Assessment of plasma cytokine profile changes in bevacizumab\u2010treated retinopathy of prematurity infants","volume":"57","author":"Kong L","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_13_9_1","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu WC","year":"2017","journal-title":"Retina"},{"key":"e_1_2_13_10_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/bjophthalmol-2016-308828","article-title":"The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: a systematic review","volume":"101","author":"Kandasamy Y","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"e_1_2_13_11_1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3928\/01913913-20200824-02","article-title":"Update on the use of anti\u2010VEGF drugs in the treatment of retinopathy of prematurity","volume":"57","author":"Seery CW","year":"2020","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"e_1_2_13_12_1","first-page":"243","article-title":"Hypertension and ischemic stroke after aflibercept for retinopathy of prematurity","volume":"13","author":"Bazvand F","year":"2020","journal-title":"Int Med Case Rep J"},{"key":"e_1_2_13_13_1","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-1814","article-title":"Hypertension and neuroimaging changes after bevacizumab for retinopathy of prematurity","volume":"145","author":"Twitty G","year":"2020","journal-title":"Pediatrics"},{"key":"e_1_2_13_14_1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.579603","article-title":"Thrombotic microangiopathy and acute kidney injury induced after intravitreal injection of vascular endothelial growth factor inhibitors VEGF blockade\u2010related TMA after intravitreal use","volume":"7","author":"Hanna RM","year":"2020","journal-title":"Front Med"},{"key":"e_1_2_13_15_1","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/ckj\/sfaa049","article-title":"Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy","volume":"13","author":"Shye M","year":"2020","journal-title":"Clin Kidney J"},{"key":"e_1_2_13_16_1","article-title":"Intravitreal bevacizumab\u2010induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab","volume":"8","author":"Hanna RM","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"key":"e_1_2_13_17_1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ebiom.2017.12.016","article-title":"Development of the human fetal kidney from mid to late gestation in male and female infants","volume":"27","author":"Ryan D","year":"2018","journal-title":"EBioMedicine"},{"key":"e_1_2_13_18_1","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1111\/j.1523-1755.2004.00621.x","article-title":"The role of vascular endothelial growth factor (VEGF) in renal pathophysiology","volume":"65","author":"Schrijvers BF","year":"2004","journal-title":"Kidney Int"},{"key":"e_1_2_13_19_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168809","article-title":"Involvement of renin\u2010angiotensin system in retinopathy of prematurity \u2014 a possible target for therapeutic intervention","volume":"11","author":"Nath M","year":"2016","journal-title":"PLoS One"},{"key":"e_1_2_13_20_1","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.kint.2019.02.042","article-title":"Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence","volume":"96","author":"Hanna RM","year":"2019","journal-title":"Kidney Int"},{"key":"e_1_2_13_21_1","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The international classification of retinopathy of prematurity revisited","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"e_1_2_13_22_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41581-018-0098-z","article-title":"Endothelium structure and function in kidney health and disease","volume":"15","author":"Jourde\u2010Chiche N","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"e_1_2_13_23_1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity","volume":"256","author":"Huang CY","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"e_1_2_13_24_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54226-7","article-title":"A new method for pharmaceutical compounding and storage of anti\u2010VEGF biologics for intravitreal use in silicone oil\u2010free prefilled plastic syringes","volume":"9","author":"Lode HE","year":"2019","journal-title":"Sci Rep"},{"key":"e_1_2_13_25_1","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/s41433-021-01922-2","article-title":"The role of anti\u2010vascular endothelial growth factor in treatment of retinopathy of prematurity\u2010a current review","volume":"36","author":"Chow SC","year":"2022","journal-title":"Eye Lond"},{"key":"e_1_2_13_26_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/11206721221099249","article-title":"Intestinal perforation after intravitreal low dose ranibizumab injection for the treatment of type 1 retinopathy of prematurity: a case report","volume":"33","author":"Rzayev T","year":"2023","journal-title":"Eur J Ophthalmol"},{"issue":"10208","key":"e_1_2_13_27_1","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open\u2010label randomised controlled trial","volume":"394","author":"Stahl A","year":"2019","journal-title":"Lancet"},{"key":"e_1_2_13_28_1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato T","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"e_1_2_13_29_1","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri SJ","year":"2007","journal-title":"Ophthalmology"},{"key":"e_1_2_13_30_1","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1002\/jcb.26777","article-title":"Increased circulation mobilization of endothelial progenitor cells in preterm infants with retinopathy of prematurity","volume":"119","author":"Babaei H","year":"2018","journal-title":"J Cell Biochem"},{"key":"e_1_2_13_31_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/pr.2015.181","article-title":"Serum concentrations of vascular endothelial growth factor in relation to retinopathy of prematurity","volume":"79","author":"Hellgren G","year":"2016","journal-title":"Pediatr Res"},{"key":"e_1_2_13_32_1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000512282","article-title":"Decreased platelet counts and serum levels of VEGF\u2010A, PDGF\u2010BB, and BDNF in extremely preterm infants developing severe ROP","volume":"118","author":"Hellgren G","year":"2021","journal-title":"Neonatology"}],"updated-by":[{"DOI":"10.1111\/ped.70414","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000}}],"container-title":["Pediatrics International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ped.70366","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ped.70366","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ped.70366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:55:17Z","timestamp":1773906917000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ped.70366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/ped.70366"],"URL":"https:\/\/doi.org\/10.1111\/ped.70366","archive":["Portico"],"relation":{},"ISSN":["1328-8067","1442-200X"],"issn-type":[{"value":"1328-8067","type":"print"},{"value":"1442-200X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70366"}}